Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7516497 | 0.94 | CHRNB4 (0.40) | CHRNB4CHRNA3CHRNB2CHRNA4LMNA | |
| SCHEMBL807163 | 0.80 | MTNR1A (0.43) | NPC1 | |
| SCHEMBL806673 | 0.80 | MTNR1A (0.43) | NPC1 | |
| SCHEMBL14024215 | 0.77 | HCRTR2 (0.36) | — | |
| SCHEMBL14023259 | 0.77 | HCRTR2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL7510749 | 0.76 | BRD4 (0.38) | GAAMAPTBRD4ATAD2 | |
| Hydrochloric Acid SCHEMBL7515873 | 0.73 | CHRNB4 (0.45) | CHRNB4CHRNA3LMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7510856 | 0.72 | ALDH1A1 (0.38) | GAAMAPTBRD4ATAD2 | |
| SCHEMBL13681594 | 0.71 | CHRNB4 (0.46) | CHRNB4CHRNA3CHRNB2CHRNA4NPC1 | |
| SCHEMBL2789738 | 0.71 | CHRNB4 (0.46) | CHRNB4CHRNA3CHRNB2CHRNA4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | HTR6, HTR3B, HTR5A | CHRNB4 141/4885CHRNA3 147/4885CHRNB2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.